When was Cellanome founded?

Cellanome was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Cellanome located?

Cellanome is headquartered in Palo Alto, United States.

How many employees does Cellanome have?

As of Aug 31, 2026, the latest employee count at Cellanome is 130.

Is Cellanome a funded company?

Cellanome is a funded company, having raised a total of $119M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 05, 2021.

When was the latest funding round of Cellanome?

Cellanome's latest funding was a $***** Series B round on Dec 23, 2025, with participation from 0 investor.

Where does Cellanome rank among its competitors?

Cellanome ranks 6th amongst 908 active competitors, of which 102 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Cellanome, which secured $75.9M in Dec, 2025.

Who are the top competitors of Cellanome?

Cellanome's top competitors include Strand Life Sciences, Novogene Corporation and BGI. Among them, Cellanome secured the most recent funding round in December, 2025.

Cellanome - 2026 Company Profile, Team, Funding & Competitors

Cellanome is a series B company based in Palo Alto (United States), founded in 2020 by Mostafa Ronaghi. It operates as a Developer of the omic data platform for researchers. Cellanome has raised $119M in funding. The company has 908 active competitors, including 102 funded and 86 that have exited. Its top competitors include companies like Strand Life Sciences, Novogene Corporation and BGI.

Company Details

Developer of the omic data platform for researchers. The company has developed a multi-omics platform that uses synthetic biology and informatics methods.

Website: www.cellanome.com/
Email ID: *****@cellanome.com

Key Metrics

Founded Year

2020

Location

Palo Alto, United States

Stage

Series B

Total Funding

$119M in 3 rounds

Latest Funding Round

Series B, Dec 23, 2025, $*****

Investors

DFJ Growth & 5 more

Ranked

6^th among 908 active competitors

Employee Count

130 as on Aug 31, 2026

Similar Companies

Strand Life Sciences & 350 more

View Cellanome's full profile

Cellanome has raised a total funding of $119M over 3 rounds. Its first funding round was on Oct 05, 2021. Cellanome has 6 institutional investors.

Here is the list of recent funding rounds of Cellanome:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 23, 2025	2421899	Series B	4526163	9646432	3555807	9840476
Mar 21, 2023	9011310	Series A	9702963	2976872	6752162	1637130
Oct 05, 2021	6038317	Seed	9421710	8995319	7692758	7782859

Access funding benchmarks and valuations. Sign up today!

View details of Cellanome's funding rounds and investors

The founders of Cellanome is Mostafa Ronaghi.

Here are the details of Cellanome's key team members:

Mostafa Ronaghi: Co-Founder of Cellanome and founder of 3 other companies, ParAllele BioScience, GRAIL and NextBio. They are also an angel investor in 4 startups.

View details of Cellanome's Founder profiles and Board Members

Cellanome's employee count trend

Cellanome has 130 employees as of Aug 26. Here is Cellanome's employee count trend over the years:

Uncover Cellanome's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellanome include Strand Life Sciences, Novogene Corporation and BGI. Here is the list of Top 10 competitors of Cellanome, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, WestBridge Capital & 92 others	74/100
2nd	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
3rd	BGI 1999, Shenzhen (China), Public	Provider of services in genome sequencing	-	Sequoia Capital China, Yunfeng Capital & 15 others	64/100
4th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	T. Rowe Price, ADIA & 22 others	63/100
5th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, Two Sigma Ventures & 10 others	62/100
6th	Cellanome 2020, Palo Alto (United States), Series B	Developer of the omic data platform for researchers	$119M	DFJ Growth, Premji Invest & 4 others	59/100
7th	Replay 2021, San Diego (United States), Acquired	Provider of genomic reprogramming platform for writing and delivering big DNA	$55M	OMX Ventures, KKR & 6 others	58/100
8th	Singular Genomics 2016, San Diego (United States), Acquired	Provider of next-generation gene sequencing and multi-omics technologies	-	Perceptive Advisors, Domain Associates & 5 others	57/100
9th	Enara Bio 2016, Oxford (United Kingdom), Series B	Developer of T-cell based cancer-cell interface for therapeutics	$84.1M	SV Health Investors, M Ventures & 36 others	53/100
10th	Allelica 2017, Rome (Italy), Seed	Provider of genomic DNA tests for assessing predisposition to diseases & personalized nutrition	$1.81M	Valor Ventures, Pi Campus & 3 others	52/100